Publications by authors named "Claes Ginman"

Claim this Profile
2
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Claes Ginman

Acta Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Miikka Lehtonen, Jorma Sormunen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Teppo Huttunen, Claes Ginman

Anticancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Per Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, Björn Tavelin, Claes Ginman

Lancet Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].
Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Lennat Åström, Lars Franzen, Claes Ginman

Eur Urol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.
Marina Forslund, Anna Ottenblad, Claes Ginman, Silvia Johansson, Peter Nygren

Support Care Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Lennart Åström, Lars Franzen, Claes Ginman

Eur Urol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Anders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, Camilla Thellenberg-Karlsson, Morten Hoyer, Claes Ginman

Lancet· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Pirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, Timo Joensuu, Ray McDermott, Petteri Hervonen, Claes Ginman

Lancet Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
Petteri Hervonen, Heikki Joensuu, Timo Joensuu, Claes Ginman, Ray McDermott

Anticancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Sophie D Fosså, Anne-Birgitte Jacobsen, Claes Ginman, Inga N Jacobsen, Sissel Overn

Eur Urol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adipose tissue concentrations of persistent organic pollutants and the risk of prostate cancer.
Lennart Hardell, Swen-Olof Andersson, Michael Carlberg, Louise Bohr, Bert van Bavel, Claes Ginman

J Occup Environ Med· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
Sten Nilsson, Peter Strang, Claes Ginman, Rolf Zimmermann, Maliha Edgren

J Pain Symptom Manage· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis